Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
23.67
-0.03 (-0.13%)
Feb 21, 2025, 4:00 PM EST - Market closed
Dianthus Therapeutics Employees
Dianthus Therapeutics had 53 employees as of December 31, 2023. The number of employees increased by 21 or 65.63% compared to the previous year.
Employees
53
Change (1Y)
21
Growth (1Y)
65.63%
Revenue / Employee
$101,245
Profits / Employee
-$1,265,887
Market Cap
700.56M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 53 | 21 | 65.63% |
Dec 31, 2022 | 32 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
DNTH News
- 23 days ago - Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences - GlobeNewsWire
- 6 weeks ago - Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results - GlobeNewsWire
- 3 months ago - Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences - GlobeNewsWire
- 4 months ago - Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting - GlobeNewsWire
- 7 months ago - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results - GlobeNewsWire
- 7 months ago - Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition - Seeking Alpha
- 8 months ago - Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) - GlobeNewsWire